← All trials
NCT01817465
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2012
- Primary completion
- Mar 1, 2014
- Completion date
- Mar 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 389
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Dong-A PharmaceuticalLead sponsor
- Kangbuk Samsung HospitalOverall official - principal investigator
- Inje UniversityOverall official - principal investigator
- Hanyang UniversityOverall official - principal investigator
- Catholic University of KoreaOverall official - principal investigator
- Chonnam National UniversityOverall official - principal investigator
- Sungkyunkwan UniversityOverall official - principal investigator
- Yonsei UniversityOverall official - principal investigator
- Daegu Catholic UniversityOverall official - principal investigator
- Konyang UniversityOverall official - principal investigator
- Seoul National UniversityOverall official - principal investigator
- Wonkwang UniversityOverall official - principal investigator
- University of UlsanOverall official - principal investigator
- Keimyung UniversityOverall official - principal investigator
- Kyungpook UniversityOverall official - principal investigator
- Soonchunhyang UniversityOverall official - principal investigator
- Ewha Womans UniversityOverall official - principal investigator
- Pusan National UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.